Full text (I Hirano et al. Gastroenterol 2020; 158: 1776-86): AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters Clinical Guidelines for the Management of Eosinophilic Esophagitis
Full text: PDF
This guideline was developed through a collaboration between AGA and the Joint Task Force for Allergy-Immunology Practice Parameters, which comprises the American Academy of Allergy, Asthma & Immunology and the American College of Allergy, Asthma & Immunology. This guideline is jointly published in Gastroenterology and Annals of Allergy, Asthma and Immunology.
Technical review article (MA Rank et al. Gastroenterol 2020; 158: 1789-1810): Technical Review on the Management of Eosinophilic Esophagitis: A Report From the AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters
Link: Clinical Decision Support Tool
Link: Treatment of EoE Spotlight Poster
Related blog posts:
A recent double-blind pilot study (n=20) (JM Spegel et al. Clin Gastroenterol Hepatol 2020; 18: 328-36) explored the use of epicutaneous immunotherapy (EPIT) in children with milk-induced eosinophilic esophagitis (EoE). 15 children received active treatment with a “Viaskin” milk allergen extract patch and 5 children received a placebo.
The premise of EPIT for EoE has been based on animal models (mouse & piglet) which have shown that epicutaneous desensitization to peanuts has been successful in preventing development of EoE.
The design of the study involved EPIT during a 9 month milk-free period followed by a milk-containing diet for 2 months. Biopsies were taken and then there was an additional 11 month open-label phase in which all patients received EPIT.
- No significant differences in mean eos/hpf in the two groups: 50 vs 48 in EPIT compared to placebo respectively.
- There were 9 of 19 (47%) had a significant drop in eosinophil count with less than 15 eos/hpf at the end of the open-label phase.
- Overall, adverse events were similar in both groups, though the EPIT group had more frequent GI adverse events than the placebo group (67% vs. 40%)
My take: The primary and secondary endpoints were not reached in this study. However, based on the open-label phase response, further studies are warranted.
Related blog posts:
Also, from Johns Hopkins: COVID19 Caseload & Outcomes Worldwide
This screenshot was taken at 2:53 pm on 3/7/20
In a report (I Hirano, ES Dellon et al. Gastroenterol 2020; 158: 111-22) on a phase 2 trial with 47 adults, the authors show that weekly subcutaneous injections of dupilumab (300 mg) was associated with improvement in eosionophilic esophagitis.
Dupilumab, a fully human monoclonal antibody, antagonizes the interleukin-4 receptor-alpha component of the type 2 receptor, thereby inhibiting signaling of IL-4 and IL-13. Dupilumab has shown “efficacy in pediatric and adult atopic dermatitis, asthma, and chronic sinusitis with nasal polyposis” and is FDA-approved for use in these disorders.
- Dupilumab was associated with improvement in dysphagia as measured by the Straumann Dysphagia Instrument with a mean reduction of 3.0 compared to 1.3 in the placebo group at week 10 (P=.0304)
- Dupilumab was associated with improvement in histology, at week 12, the peak eosinophil count had dropped by a mean of 86.8 (P<.0001 vs. placebo)
- Dupilumab was associated with improvement in endoscopic parameters as assessed by endoscopic reference score which dropped by 1.6 (P -.0006 vs placebo)
- No serious adverse effects were evident. Nasopharyngitis was noted in 17% in the dupilumab group compared to 4% of placebo-treated patients. Injection site erythema was noted in 35% (vs. 8% in placebo group
Of note, the study was sponsored by pharmaceutical companies and many of the authors (including both lead authors) were either affiliated with these companies.
My take: This study indicates that Dupilumab has at least short term efficacy and safety for eosinophilic esophagitis.
Related blog posts:
Disclaimer: This blog, gutsandgrowth, assumes no responsibility for any use or operation of any method, product, instruction, concept or idea contained in the material herein or for any injury or damage to persons or property (whether products liability, negligence or otherwise) resulting from such use or operation. These blog posts are for educational purposes only. Specific dosing of medications (along with potential adverse effects) should be confirmed by prescribing physician. Because of rapid advances in the medical sciences, the gutsandgrowth blog cautions that independent verification should be made of diagnosis and drug dosages. The reader is solely responsible for the conduct of any suggested test or procedure. This content is not a substitute for medical advice, diagnosis or treatment provided by a qualified healthcare provider. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a condition
About two years ago, James Franciosi presented research at NASPGHAN meeting indicating that the main difference between children with eosiniophilic esophagitis (EoE) who respond to proton pump inhibitiors (PPIs) compared to those who do not was related to their metabolism of PPIs and not related to the nature of their underlying EoE.
Related blog: #NASPGHAN17 Eosionophilic Esophagitis Session
Now, more has been published on this topic: EB Mougey et al. JPGN 2019; 69: 581-7.
In this study with 92 patients, data was collected from participants in a prospective clinical trial of high-dose PPI for EoE.
- 57 (62%) were responsive to PPIs and 35 (38%) were not responsive to PPIs
- Carriage of STAT6 allele variant rs1059513 predicted responsiveness to PPIs with OR of 6.16
- Carriage of STAT6 rs324011 synergizes with CYP2C19*17 to predict PPI-nonresponsive EoE
- Carriers of CYP2C19*17 are more likely to fail PPIs for EoE. Children with CYP2C19*17 gain of function “have a 7.7 fold better odds of failing PPI therapy” than noncarriers.
- CYP2C19*17 effects “appears to be exerted within a specific range of PPI doses…and does not appear to exert influence at the low and high ends of this dose range.”
- STAT6, which in this study is a cofactor, “upregulates transcription of CCL26 (eostaxin-3) 53-fold in esophageal eosinophilia relative to levels in peptic esophagitis and 490-fold over levels found in normal esophageal biopsies.”
- PPIs effectiveness “does not correlate with esophageal” acid exposure; thus, its effects are mediated via an anti-inflammatory mechanism.
My take: This study indicates that genotype-guided dosing of PPIs for the treatment of EoE is likely to be worthwhile.
View from Yonah Mountain, GA
Full Text Link: A Conceptual Approach to Understanding Treatment Response in Eosinophilic Esophagitis
Also, related articles:
- D Bushyhead et al. Gastroenterology 2019; 157: 944-5. This practical teaching case report noted that oral immunotherapy (OIT) has been shown to trigger new onset EoE in 2.7% (AJ Lucendo et al. Ann Allergy Asthma Immunol 2014; 113: 624-9).
- R Alexander et al. Clin Gastroenterol Hepatol 2019; 17: 2371-3. This study compared eating behaviors of adults with active EoE (n=10), inactive EoE (n=10) and control patients (n=10). Not surprisingly, those with active EoE took longer to eat (18.3 min compared to 12.4 min, and 13.0 min respectively) and had more drinks after a single bite (11.6 compared with 5.1 and 2.5 respectively)
Related blog posts:
Link to full NASPGHAN 2019 Abstracts.
Here are some abstracts that I found interesting at this year’s NASPGHAN meeting:
- Off-label use of topiramate may be helpful in stabilizing weight and improving NAFLD
- Socioeconomic barriers are frequent in NAFLD patients (the 2nd poster did not appear to show a control population):
Primary Sclerosing Cholangitis -Use of Vedolizumab for PSC did not appear to help
- EoE is four times more likely in this cohort with inflammatory bowel disease
- 2nd poster describes very early-onset EoE
Inflammatory Bowel Disease:
- Use of infliximab in VEO IBD. Used in 46/122 (38% of patients) and 50% had persistent use 3 years later
Enteral nutrition –poster from our group describing good tolerance of plant-based formula (with Ana Ramirez).
Celiac disease. This poster indicates low yield of additional serology for celiac disease besides TTG IgA and serum IgA. This includes testing in young patients (< 2 years) with celiac disease.
A recent study (JL Yasuda et al. JPGN 2019; 69: 163-70) shows that esophagitis is common with and without proton pump inhibitor (PPI) therapy in children with esophageal atresia (EA).
Background: This study encompassed 310 patients (34% long gap EA) and 576 endoscopies (median age 3.7 years)
- Erosive esophagitis was found in 8.7% of patients.
- 15.2% of patients had esophagitis with >15 eos/hpf; 49% of patients had ≥1 eos/hpf (histologic eosinophilia)
- 87% of endoscopies were preceded by acid suppression therapy; being on acid suppression reduced the odds for abnormal esophageal biopsy (P=0.011).
- Histologic esophagitis was “highly prevalent even with high rates of acid suppressive medications use.”
- For example, among those receiving PPI monotherapy, 150 had normal biopsy and 136 had abnormal biopsy. Among those off all acid suppression, 30 had normal biopsy and 45 had abnormal biopsy.
- For erosive esophagitis, this occurred in 12 on PPI and was not present in 274 on PPI therapy. Among those off all acid suppression, 4 had erosive esophagitis and 70 did not.
- Presence or integrity of fundoplication was not significantly associated with esophagitis.
While this is a large study, the findings have several limitations. This is a single center retrospective study and this center attracts highly complex cases of EA.
My take: In addition to fairly high rates of erosive esophagitis and eosinophilic esophagitis, this study shows a high incidence of microscopic esophagitis, the significance of this is unclear. This study supports the current recommendations of 3 endoscopies in childhood and perhaps more frequent surveillance in those with more complex EA.
Related blog posts:
Sign in Hood River, OR